Silicon Valley-Based Silk Road Medical Announces Expansion to MSP Region
Silk Road Medical (NASDAQ: SILK) has announced the opening of a new office in Plymouth, Minnesota, in response to the growing demand for TransCarotid Artery Revascularization (TCAR) procedures. This expansion aims to enhance operational capabilities and access local talent, contributing to significant job growth. Silk Road's new facility in Medical Alley complements its existing presence in Silicon Valley and focuses on stroke prevention technology. Additionally, the company has received recognition as a Great Place to Work with 95% employee satisfaction.
- New office opening in Plymouth, Minnesota to meet growing demand for TCAR procedures.
- Expansion to enhance operational capabilities and access local talent.
- Expected significant job growth in the Minnesota area.
- Recognition as a Great Place to Work with 95% employee satisfaction.
- None.
SUNNYVALE, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, recently announced the opening of a new office in Plymouth, Minnesota, to accommodate growing demand for TransCarotid Artery Revascularization (TCAR) and to access the local talent pool of aspiring and experienced med tech professionals.
“We continue to invest in our long-term growth and are excited to expand our operations to include a facility in Plymouth. Medical Alley has a rich history of technological innovation and serves as a great complement to our continued and growing presence in Silicon Valley,” said Erica Rogers, President and Chief Executive Officer of Silk Road Medical.
The new location extends Silk Road Medical’s footprint and provides further operational capability to meet growing interest in the company’s less invasive stroke prevention technology. In addition to increased R&D infrastructure, Silk Road Medical anticipates significant job growth as they expand their Minnesota presence.
This announcement comes on the heels of Silk Road Medical being certified as a Great Place to Work; the only recognition based entirely on what employees report about their workplace experience.
“The addition of Silk Road Medical to the Greater MSP region will deepen our strength in cutting-edge medical technologies and bring new jobs in research and manufacturing,” said Peter Frosch, President and CEO of GREATER MSP. “We look forward to working with Silk Road’s leadership team to support their success and growth in the years ahead.”
“We are thrilled to welcome Silk Road Medical to Minnesota’s economy and congratulate them on their growth,” said Minnesota Department of Employment and Economic Development Commissioner Steve Grove. “This expansion outside of California to Minnesota will be met with opportunities to continue growth with our innovative, talented workforce and strong business climate.”
“We are excited to welcome Silk Road Medical and their groundbreaking technology to Plymouth,” said Danette Parr, Economic Development Manager for the City of Plymouth. “We wish them great success as they continue to grow.”
About TCAR with the ENROUTE Transcarotid Neuroprotection and Stent System
TCAR (TransCarotid Artery Revascularization) is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. The ENROUTE Transcarotid Stent is intended to be used in conjunction with the ENROUTE Transcarotid Neuroprotection System (NPS) during the TCAR procedure. The ENROUTE Transcarotid NPS is a first in class device used to directly access the common carotid artery and initiate high rate temporary blood flow reversal to protect the brain from stroke while delivering and implanting the ENROUTE Transcarotid Stent.
About Silk Road Medical
Silk Road Medical, Inc. (NASDAQ: SILK), is a medical device company located in Sunnyvale, California, that is focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter clinical thinking, visit www.silkroadmed.com and connect on Twitter, LinkedIn and Facebook.
About GREATER MSP
GREATER MSP is the economic development partnership for the 15-county Minneapolis Saint Paul region. Over 300 leading businesses, universities, cities, counties, philanthropies, and others are working together to accelerate the competitiveness of the regional economy and drive inclusive economic growth through job creation, capital investment and the execution of strategic initiatives. For more information go to greatermsp.org.
Investors:
Lynn Lewis or Caroline Paul
Gilmartin Group
investors@silkroadmed.com
Media:
Michael Fanucchi
Silk Road Medical
mfanucchi@silkroadmed.com
Maggie Habashy
GREATER MSP
Maggie.habashy@greatermsp.org
FAQ
What are the recent developments for Silk Road Medical (SILK)?
How does the new office in Minnesota benefit Silk Road Medical?
What is TransCarotid Artery Revascularization (TCAR)?
How well is Silk Road Medical rated by its employees?